Fund shareholders of AC Immune SA
ISIN CH0329023102 · Switzerland · LEI 967600VLQ0ZC2HSOG765
- Fund shareholders
- 16
- Of which ETFs
- 7 9 other funds
- Value held
- ≈ 1.8M $ 1.7M $ · 96.2K €
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| iShares Biotechnology ETF iShares Trust | 432,868 | 1M $ | 0.01 % | as of Jun 30, 2026 ↗ |
| Dimensional U.S. Small Cap ETF Dimensional ETF Trust | 80,741 | 176.8K $ | 0.00 % | as of Jul 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 63,601 | 169.2K $ | 0.00 % | as of May 31, 2026 ↗ |
| U.S. SMALL CAP PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 45,388 | 99.4K $ | 0.00 % | as of Jul 31, 2026 ↗ |
| U.S. MICRO CAP PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 44,072 | 96.5K $ | 0.00 % | as of Jul 31, 2026 ↗ |
| U.S. VECTOR EQUITY PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 15,821 | 34.6K $ | 0.00 % | as of Jul 31, 2026 ↗ |
| JNL/DFA U.S. Small Cap Fund JNL Series Trust | 7,966 | 19K $ | 0.00 % | as of Jun 30, 2026 ↗ |
| Dimensional U.S. Core Equity 2 ETF Dimensional ETF Trust | 7,863 | 17.2K $ | as of Jul 31, 2026 ↗ | |
| Dimensional US Core Equity 1 ETF Dimensional ETF Trust | 5,748 | 12.6K $ | 0.00 % | as of Jul 31, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 5,312 | 14.1K $ | 0.02 % | as of May 31, 2026 ↗ |
| AST Small-Cap Equity Portfolio Advanced Series Trust | 4,330 | 10.3K $ | 0.00 % | as of Jun 30, 2026 ↗ |
| iShares Neuroscience and Healthcare ETF iShares Trust | 3,783 | 8.3K $ | 0.15 % | as of Jul 31, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 3,721 | 9.9K $ | 0.01 % | as of May 31, 2026 ↗ |
| Dimensional US Sustainability Core 1 ETF Dimensional ETF Trust | 2,823 | 6.2K $ | 0.00 % | as of Jul 31, 2026 ↗ |
| Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds | 98 | 233.2 $ | as of Jun 30, 2026 ↗ | |
| TOP CLASS HEALTHCARE, FI RENTA 4 GESTORA, S.G.I.I.C., S.A. | 96.2K € | 0.72 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| TOP CLASS HEALTHCARE, FI RENTA 4 GESTORA, S.G.I.I.C., S.A. | 0.72 % | as of Dec 31, 2025 ↗ |
| iShares Neuroscience and Healthcare ETF iShares Trust | 0.15 % | as of Jul 31, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 0.02 % | as of May 31, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 0.01 % | as of May 31, 2026 ↗ |
| iShares Biotechnology ETF iShares Trust | 0.01 % | as of Jun 30, 2026 ↗ |
| JNL/DFA U.S. Small Cap Fund JNL Series Trust | 0.00 % | as of Jun 30, 2026 ↗ |
| Dimensional U.S. Small Cap ETF Dimensional ETF Trust | 0.00 % | as of Jul 31, 2026 ↗ |
| U.S. MICRO CAP PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 0.00 % | as of Jul 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| U.S. VECTOR EQUITY PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 0.00 % | as of Jul 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 15 | -1 | 724,135 | -3.1 % |
| 2026Q2 | 16 | -2 | 747,034 | +11.2 % |
| 2026Q1 | 18 | +2 | 671,587 | +22.1 % |
| 2025Q4 | 16 | -3 | 549,817 | -5.0 % |
| 2025Q3 | 19 | -7 | 578,989 | -49.1 % |
| 2025Q2 | 26 | +2 | 1,137,575 | -38.0 % |
| 2025Q1 | 24 | +3 | 1,834,102 | -0.5 % |
| 2024Q4 | 21 | +8 | 1,842,523 | +9.3 % |
| 2024Q3 | 13 | -2 | 1,685,202 | -0.5 % |
| 2024Q2 | 15 | +5 | 1,693,541 | +276.7 % |
| 2024Q1 | 10 | +3 | 449,585 | +437.5 % |
| 2023Q4 | 7 | 83,650 |
Cite this page
Titelia. "Fund shareholders of AC Immune SA". https://titelia.com/en/stocks/ac-immune-sa-CH0329023102